SEER reported Q1 2026 results after the close on May 13 — a revenue miss against a weak consensus, offset by reaffirmed full-year guidance. That combination keeps the stock at a crossroads: a tiny research-tools name that has lost half its short interest in six weeks, picked up its first new analyst coverage in years, and is trading at $1.82 with the Street's single price target pointing to more than double that.
The earnings print itself was soft. Q1 revenue came in at $2.79M, missing the $3.60M estimate, and EPS of -$0.30 missed the -$0.29 consensus. The company also filed a patent infringement suit against Nanomics Biotechnology on the same day — an aggressive move for a company at this market cap that signals management is actively defending its core proteomics platform. Crucially, full-year 2026 sales guidance of $16M–$18M was reaffirmed, bracketing the $17.05M Street estimate. That held guidance is likely the most important number in the release, because it tells investors the miss was execution timing rather than a demand problem.
Short interest does not tell a story of mounting conviction from bears. At under 0.8% of the free float, positioned short here is almost negligible. More telling is the direction: SI has fallen nearly 50% over the past month, dropping from roughly 790,000 shares shorted in early April to just 403,000 now. The borrow market confirms shorts are stepping back — cost to borrow has eased to 0.67%, its lowest level of the recent period and down about 15% on the week. Availability is generous. The ORTEX short score of 29.5 is well within neutral territory, ranking in the 85th percentile for low short pressure. This is not a stock where bears are pressing.
The clearest recent Street development is the Canaccord Genuity initiation on May 4. The firm launched with a Buy and a $4.00 target — the only active formal analyst coverage on the stock. That target, at a 120% premium to the current price, is the entire bull case in one number. The note that consensus reads as "Buy" reflects this single initiation rather than a broad analyst base. All earlier published targets — Morgan Stanley's $3 (August 2024) and BofA's $6.50 (January 2023) — are stale and should not be weighted heavily. What matters is that fresh coverage arrived with a clear upside thesis just nine days ago, even as the stock slipped about 2% on the week and the Q1 print disappointed.
Ownership concentration is worth noting. SoftBank holds 9.1% and sits completely flat in its position. aMoon Ventures holds 8.7%, also unchanged. Founder and CEO Omid Farokhzad controls 7.8% — and has been selling in small, regular tranches at prices near the current level, most recently in February 2026. The CFO follows the same pattern. These are modest rule-10b5-1-style drips rather than conviction sales, and the amounts (under $70,000 per transaction) are immaterial at the company level. The more interesting holder move is Bradley Radoff, who added 930,810 shares as of April 12, lifting his stake to 3.7%. That is a sizeable addition for a name this small.
The week ahead is defined by the market's reaction to the Q1 print. The previous earnings in February 2026 produced a 16.8% single-day drop, so the bar for a negative reaction is established. Whether the reaffirmed guidance and the patent filing land as net positives, and whether the Canaccord Buy holds up against what appears to be a structurally slow-burn revenue ramp, is the question traders will be working through in the sessions ahead.
See the live data behind this article on ORTEX.
Open SEER on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
